In this episode, hear about the fully remote TRACK (Target Rare Cancer Knowledge) clinical trial and its unique approach to providing access to biomarker testing for patients in community care settings by leveraging technology.
Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
As care teams seek new ways to engage and support patients with rare cancers, CANCER BUZZ speaks with Jim Palma, executive director of TargetCancer Foundation, a patient-founded nonprofit organization dedicated to supporting patients living with, and researchers focused on, rare cancers. In this episode, hear about the fully remote TRACK (Target Rare Cancer Knowledge) clinical trial and its unique approach to providing access to biomarker testing for patients in community care settings by leveraging technology.
"It [access to biomarker testing] really is one of the biggest challenges that patients with rare cancer face, as well as access to interpretation of results in a way that leads them to the right treatment. So, what we’ve done is developed a [fully remote] clinical trial that offers testing to patients at no cost and eases their ability to enroll in the trial through remote consenting." – Jim Palma, Executive Director
Jim Palma
Executive Director
TargetCancer Foundation
Cambridge, MA
This is the third episode in a podcast series developed in connection with the ACCC education program Emerging Biomarkers: Innovative Therapies for NTRK Gene Fusion Testing and was made possible with support by Bayer.
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
October 28, 2026
September 10, 2026
